Skip to content

赞科

US · XNCR #2825 按市值排名 上市于 1970
22.85 -1.15 -4.79%
实时 - 追踪5344个代码 - 心跳于27秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 3.60 高于历史水平 第96百分位
5年平均 2.09 · 在Biotechnology中排名第327/514
市盈率 -11.28 低于历史水平 第16百分位
5年平均 -22.12 · 前瞻 -7.48
市销率 17.25 高于历史水平 第94百分位
5年平均 9.26 · 前瞻 15.39 · 在Biotechnology中排名第204/388

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
赞科 (XNCR) 1.70B -10.58 3.38 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值24.11 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算5.5%。

合理价值

Xencor Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% premium over our quantitative fair value estimate of $24.11 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's lack of profitability weakens our quantitative valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 5.6% lies in the bottom 10% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are expensive.

Conversely, the company's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 6.4, a core component of leverage, sits in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

赞科 讨论区 0 条评论

发表评论